Entero Therapeutics IncNASDAQ:ENTONASDAQ FSI:H. Deficient and Delinquent (Issuer failed to meet continued listing requirements and missed regulatory filing deadline)
- LAST PRICE0.3437
- TODAY'S CHANGE (%)-0.0042 (-1.2072%)
- Bid / Lots0.3392/ 1
- Ask / Lots0.3600/ 480
- Open / Previous Close0.3480 / 0.3479
- Day Range
- 52 Week Range
- Volume26,558
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENTO |
|---|---|---|
| 09:34 ET | 320 | 0.352 |
| 09:45 ET | 900 | 0.348 |
| 09:54 ET | 200 | 0.348 |
| 10:14 ET | 100 | 0.350822 |
| 10:15 ET | 172 | 0.352 |
| 10:33 ET | 214 | 0.3392 |
| 11:06 ET | 100 | 0.3392 |
| 12:03 ET | 296 | 0.352 |
| 12:20 ET | 200 | 0.352 |
| 12:38 ET | 2099 | 0.352 |
| 12:41 ET | 200 | 0.348 |
| 12:43 ET | 200 | 0.3519 |
| 12:48 ET | 458 | 0.34355 |
| 12:50 ET | 407 | 0.3436 |
| 12:54 ET | 296 | 0.347 |
| 01:24 ET | 2500 | 0.3469 |
| 01:26 ET | 5000 | 0.3469 |
| 02:49 ET | 100 | 0.3401 |
| 02:54 ET | 280 | 0.347 |
| 03:09 ET | 140 | 0.3435 |
| 03:14 ET | 5200 | 0.3402 |
| 03:20 ET | 200 | 0.3401 |
| 03:38 ET | 2940 | 0.347 |
| 03:39 ET | 1000 | 0.346831 |
| 03:43 ET | 383 | 0.347 |
| 03:50 ET | 219 | 0.347 |
| 03:52 ET | 150 | 0.3469 |
| 03:59 ET | 538 | 0.3437 |
Sep 10, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Entero Therapeutics Inc | 863.8K | 0.0x | --- |
Agentix Corp | 906.0K | -3.4x | --- |
Ayala Pharmaceuticals Inc | 852.7K | 0.0x | --- |
Molecular Pharmacology (USA) Ltd | 799.6K | -1.0x | --- |
GlobeStar Therapeutics Corp | 697.8K | -0.2x | --- |
Pharmagreen Biotech Inc | 995.5K | -6.7x | --- |
Company Information
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.
Contact Information
- Headquarters
- 777 Yamato Road, Suite 502BOCA RATON, FL, United States 33431
- Phone
- 561-589-7020
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- James Sapirstein
- President, Director
- Jack Syage
- Chief Financial Officer
- Sarah Romano
- Lead Independent Director
- Edward Borkowski
- Director
- Timothy Ramdeen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $863.8K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.37 |
EPS | $-51.90 |
Book Value | $2.31 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
